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Introduction
Cluster randomized trials (CRTs), also known as group
randomized, place-based, or community intervention trials, are
increasingly important for the evaluation of interventions in health
research [1–7]. In CRTs, groups, or ‘‘clusters’’, of individuals—
rather than the constituent individuals themselves—are randomly
allocated to study arms, and outcomes are then measured on the
individual cluster members. Examples of clusters include medical
practices, hospital wards, schools, and communities. CRTs often
evaluate complex or multifaceted interventions targeted at the
cluster, professionals, or individual cluster members. (See Text S1
for a glossary of terms.)
CRTs pose distinct ethical challenges for several reasons. First, in
CRTs the units of allocation, intervention, and outcome measure-
ment may differ in a single trial. For example, in a CRT of teaching
a new hand-washing technique to help avoid transmitting infection
on hospital wards, the unit of allocation may be the hospital, the
intervention may be delivered to health professionals, and data may
be collected about or from patients. This has implications for
identifying research participants and for informed consent proce-
dures. Second, in some CRTs interventions are administered at the
cluster level and thus have the potential to directly or indirectly
affect the interests of many individuals associated with a cluster,
including those quite remote from the study itself. For example, in a
community randomized trial of a mass media advertising campaign
to promote smoking cessation, the intervention may potentially
affect all community residents as well as visitors and those traveling
through the study communities. Third, in CRTs clusters are
commonly randomized before it is possible to identify and recruit
individuals for informed consent, thus consent to randomization
may not be obtained. Fourth, cluster-level study interventions may
be difficult or impossible for individuals to avoid, thereby precluding
the meaningful refusal of study participation. Fifth, CRTs often
employ social groups or organizations as the units of allocation, but
current understanding of the moral status of such groups, and of the
gatekeepers who speak on their behalf, is incomplete. Sixth, whereas
risks to individuals may be minor, the risks to the cluster as a whole
or to subgroups may be significant, because risks to the group may
be underestimated, and vulnerable subgroups within clusters may
be difficult to identify.
Although there is a small but growing literature on the subject
[8–13], the ethical challenges raised by CRTs have yet to be
systematically explored. As a result, researchers and research
ethics committees (RECs) currently lack specific guidelines to help
them design, conduct, and review CRTs according to interna-
tionally accepted ethical standards. Predictably, the lack of
comprehensive guidance has resulted in uncertainty and markedly
different interpretations as to permissible ethical practices in
CRTs, both within and across countries.
The aim of this consensus statement is to provide guidance on
the ethical design and conduct of CRTs in health research. This
guidance is primarily intended for researchers and RECs. It will
also be relevant to other groups such as research funders, policy
makers, journal editors, and potential study participants. It builds
upon—but does not replace—national and international ethics
guidelines for randomized controlled trials and other human
research. The consensus statement should be interpreted in light of
the laws and regulations of the host country or countries, as well as
other applicable international standards.
Methods
The development of the consensus statement was underpinned
by a five-year research project funded by the Canadian Institutes of
Health Research [14]. The project used a mixed methods approach
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incorporating both empirical work and ethical analysis. The
empirical work included interviews with key informants, review of
published CRTs [15], a survey of trialists, and a survey of REC
chairs. Based on the empirical work, as well as the practical
experiences of research team members, the team identified six
questions specific to CRTs in need of further analysis: How should
research participants be identified? From whom, how, and when
must informed consent be obtained? Does clinical equipoise apply?
How does one determine if the benefits outweigh the risks? Who are
gatekeepers, and what are their responsibilities? How ought
vulnerable groups be protected [16]? The research team conducted
an ethical analysis of each issue, which led to a series of discussion
papers laying out principles, policy options, and rationales for
proposed ethics guidelines [17–20]. The research team posted these
papers on a wiki (http://crtethics.wikispaces.com) and publicized
the wiki in the discussion papers and surveys.
To develop the consensus statement from this process, the
research team organized a two-and-a-half-day meeting of a
multidisciplinary expert panel that took place in Ottawa, Canada,
in November 2011. The research team identified the constituen-
cies and perspectives that needed to be represented within the
expert panel, including ethicists, cluster trialists, consumer
representatives, RECs, policy makers, funding agencies, and
journal editors. Potential expert panel members were identified
by consultation with colleagues, via searches of the relevant
literature and the Internet, and from respondents in the key
informant interviews, trialist survey, and REC chair survey. In
addition to six of the members of the research team, 26 external
individuals were approached, of whom 13 agreed to participate.
(See Text S2 for a list of the 19-member expert panel.) External
members were invited as individuals rather than as representatives
of their home organizations.
The research team made the discussion papers available to the
expert panel in advance of the meeting. The first day of the
consensus process was an open meeting with a simultaneous
webcast, attended by individuals from the same constituencies and
sources used to identify the expert panel. Eighty people
participated in person, and a further 20 participated by webcast.
The research team presented the results of the empirical studies
and the ethical analyses of the six questions, and three expert
discussants and the audience commented on the presentations.
The open meeting served to further familiarize the expert panel
with the content of the materials developed by the research team,
and allowed them to hear issues raised about the materials by the
broader audience. Video of the open portion of the consensus
meeting is available via YouTube (http://www.youtube.com/
user/mtaljaard55).
Over the next one and a half days the members of the expert
panel met in closed session to discuss the identified issues and to
develop recommendations. The expert panel was chaired by
Professor Martin Eccles, an experienced small group leader with
expertise in chairing guideline development groups. Initial
discussions established the ‘‘rules of engagement’’ for the expert
panel process. The expert panel agreed about how debate should
be conducted and how they wanted the chair to run the process.
The expert panel agreed to achieve consensus, where possible,
through discussion and would document disagreements; they did
not wish to use a majority voting system. Draft recommendations
based upon the background papers were presented to the expert
panel, and members were asked to identify issues in need of
clarification and discussion. Full discussion of these issues was
facilitated by the chair with the aim of achieving consensus on the
underlying principles, but not necessarily specific wording. All
expert panel members actively participated in the discussion.
Some draft recommendations were substantially revised during the
process. There were no substantive disagreements requiring
presentation of dissenting views.
A writing group, consisting of seven members of the research
team, then reviewed the results of the meeting and produced a first
draft of the consensus statement. The writing group circulated the
draft to the expert panel in December 2011 and asked for
comments on both the principles and specific wording of the
recommendations. Responses were received from all participants,
and a point-by-point response to all comments (available on
request) was produced and the draft consensus statement revised
accordingly. In February 2012, the writing group posted the
revised consensus statement on the wiki and invited the expert
panel, participants of the open meeting, respondents in the key
informant interviews, trialist survey, and REC chair survey, and
other contacts of the research team to comment. Again, the
writing group produced a point-by-point response to all comments
(available on request) and revised the consensus statement. In June
2012, the final draft of the consensus statement was sent to the
expert panel for approval, which was given by all members with no
dissention.
Results
General ethical principles govern the design and conduct of
health research (see Text S3 for general ethical principles). The 15
recommendations in the Ottawa Statement consider the applica-
tion of these ethical principles to the design and conduct of CRTs
(see Table 1). The recommendations are intended to guide
researchers in the design and conduct of CRTs, and to ensure
robust and appropriate review of CRTs by RECs. The recom-
mendations are organized by the six identified ethical issues, and
each recommendation is followed by a brief explanation or
interpretation.
Summary Points
N In cluster randomized trials (CRTs), the units of allocation,
intervention, and outcome measurement may differ
within a single trial. As a result of the unique design of
CRTs, the interpretation of existing research ethics
guidelines is complicated.
N The Ottawa Statement on the Ethical Design and
Conduct of Cluster Randomized Trials aims to provide
researchers and research ethics committees (RECs) with
detailed guidance on the ethical design, conduct, and
review of CRTs.
N A five-year mixed methods research project explored the
ethical challenges of CRTs. Empirical studies document-
ed the reporting of ethical issues in published CRTs,
interviewed experienced trialists, and surveyed trialists
and REC chairs. The ethical issues identified were
explored in a series of background papers that provided
detailed ethical analyses and policy options, and a panel
of experts using a systematic process developed a
consensus statement.
N The Ottawa Statement sets out 15 recommendations for
the ethical design and conduct of CRTs. The recommen-
dations provide guidance on the justification of a cluster
randomized design, the need for REC review, the
identification of research participants, obtaining in-
formed consent, the role of gatekeepers in protecting
group interests, the assessment of benefits and harms,
and the protection of vulnerable participants.
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Justifying the Cluster Randomized Design
Recommendation 1: Researchers should provide a
clear rationale for the use of the cluster randomized
design and adopt statistical methods appropriate for
this design.
Compared with an individually randomized trial with the same
number of individuals, CRTs are inefficient and have less
statistical power. This is a result of the tendency for responses of
individuals within a cluster to be more similar than the responses
of individuals in differing clusters. Furthermore, CRTs are more
likely than individually randomized trials to have imbalances
across study arms at baseline because they tend to have a smaller
number of randomized units (e.g., a median of 21 clusters in total
in a review of a random sample of 300 published CRTs [15]).
CRTs are also more susceptible to various forms of bias, including
selection bias, especially when individual participants need to be
identified or enrolled after cluster allocation [21]. Given its inherent
statistical inefficiency and methodological complexities, the use of
cluster as opposed to individual randomization should be clearly
justified.
Reasons for adopting the CRT design are diverse, and range
from sheer necessity (because the intervention can only be
administered at the cluster level) to other scientific, practical, or
logistical reasons [1]. Common reasons for cluster randomization
include the following: to avoid experimental contamination due to
intervention and control participants in the same cluster interact-
ing with each other; to enhance participant compliance or
cooperation of investigators; to capture the indirect effects of an
intervention against infectious diseases (i.e., the effects of herd
immunity); for administrative convenience; or to reduce the costs
of administering the intervention across a large geographic area.
An inappropriate reason to adopt a CRT is the mistaken belief
Table 1. Summary of recommendations.
Ethical Issue
Recommendation
Number Recommendation
Justifying the cluster
randomized design
1 Researchers should provide a clear rationale for the use of the cluster randomized design and adopt statistical
methods appropriate for this design.
REC review 2 Researchers must submit a CRT involving human research participants for approval by a REC before commencing.
Identifying research
participants
3 Researchers should clearly identify the research participants in CRTs. A research participant can be identified as an
individual whose interests may be affected as a result of study interventions or data collection procedures, that is, an
individual (1) who is the intended recipient of an experimental (or control) intervention; or (2) who is the direct target
of an experimental (or control) manipulation of his/her environment; or (3) with whom an investigator interacts for
the purpose of collecting data about that individual; or (4) about whom an investigator obtains identifiable private
information for the purpose of collecting data about that individual. Unless one or more of these criteria is met, an
individual is not a research participant.
Obtaining informed
consent
4 Researchers must obtain informed consent from human research participants in a CRT, unless a waiver of consent is
granted by a REC under specific circumstances.
5 When participants’ informed consent is required, but recruitment of participants is not possible before randomization
of clusters, researchers must seek participants’ consent for trial enrollment as soon as possible after cluster
randomization—that is, as soon as the potential participant has been identified, but before the participant has
undergone any study interventions or data collection procedures.
6 A REC may approve a waiver or alteration of consent requirements when (1) the research is not feasible without a
waiver or alteration of consent, and (2) the study interventions and data collection procedures pose no more than
minimal risk.
7 Researchers must obtain informed consent from professionals or other service providers who are research
participants unless conditions for a waiver or alteration of consent are met.
Gatekeepers 8 Gatekeepers should not provide proxy consent on behalf of individuals in their cluster.
9 When a CRT may substantially affect cluster or organizational interests, and a gatekeeper possesses the legitimate
authority to make decisions on the cluster or organization’s behalf, the researcher should obtain the gatekeeper’s
permission to enroll the cluster or organization in the trial. Such permission does not replace the need for the
informed consent of research participants.
10 When CRT interventions may substantially affect cluster interests, researchers should seek to protect cluster interests
through cluster consultation to inform study design, conduct, and reporting. Where relevant, gatekeepers can often
facilitate such a consultation.
Assessing benefits
and harms
11 The researcher must ensure that the study intervention is adequately justified. The benefits and harms of the study
intervention must be consistent with competent practice in the field of study relevant to the CRT.
12 Researchers must adequately justify the choice of the control condition. When the control arm is usual practice or no
treatment, individuals in the control arm must not be deprived of effective care or programs to which they would
have access, were there no trial.
13 Researchers must ensure that data collection procedures are adequately justified. The risks of data collection
procedures must (1) be minimized consistent with sound design and (2) stand in reasonable relation to the
knowledge to be gained.
Protecting vulnerable
participants
14 Clusters may contain vulnerable participants. In these circumstances, researchers and RECs must consider whether
additional protections are needed.
15 When individual informed consent is required and there are individuals who may be less able to choose participation
freely because of their position in a cluster or organizational hierarchy, RECs should pay special attention to
recruitment, privacy, and consent procedures for those participants.
doi:10.1371/journal.pmed.1001346.t001
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that the need to seek informed consent can be avoided by using
cluster randomization.
Once a clear rationale for the cluster randomized design has
been established, investigators should adopt statistical methods
appropriate for this design. Because multiple observations from the
same cluster are usually positively correlated, standard statistical
methods for sample size calculation and data analysis are invalid.
Several articles provide appropriate methods for sample size
calculation and analysis for CRTs [22–27].
REC Review
Recommendation 2: Researchers must submit a CRT
involving human research participants for approval by a
REC before commencing.
There is broad agreement in national and international research
ethics guidelines that all human research should be submitted to
and approved by a REC. Whereas the integrity of researchers is an
important protection for research participants, researchers may
have vested interests. RECs are better placed to ensure that the
autonomy and welfare interests of research participants are
protected, and that national and international ethics standards
are upheld.
Research may usefully be defined as a systematic investigation
that is designed to produce generalizable knowledge. Quality
improvement initiatives that seek solely to improve local service
delivery are (generally) not regarded as research and may not
require REC review. However, CRTs, including those evaluating
quality improvement and knowledge translation interventions, are
clearly designed to produce generalizable knowledge and, as a
result, must be reviewed and approved by a REC. This includes
CRTs conducted outside health care settings, such as in education
or public health research.
Health research must be reviewed in a manner that ensures that
ethical issues receive appropriate consideration. Studies vary in the
magnitude and complexity of ethical issues posed. As a result,
RECs ought to undertake a proportional approach to the review of
study protocols. According to this approach, CRTs that pose
substantial risk or involve vulnerable participants ought to receive
intensive scrutiny; in contrast, CRTs that pose low risk and do not
involve vulnerable participants may be eligible for an expedited or
delegated review.
Identifying Research Participants
The clear identification of research participants is central to the
implementation of protections outlined in national and interna-
tional ethics guidelines. Research participants are those most
directly affected by the conduct of research, and researchers and
RECs have an obligation to protect the interests of research
participants. We offer four criteria to guide the appropriate
identification of human research participants in a CRT based on a
defining feature of research participants [18]. The criteria attempt
to precisely delineate whose interests are sufficiently directly
affected that they ought to be considered research participants.
Recommendation 3: Researchers should clearly iden-
tify the research participants in CRTs. A research
participant can be identified as an individual whose
interests may be affected as a result of study interven-
tions or data collection procedures, that is, an individual
(1) who is the intended recipient of an experimental (or
control) intervention; or (2) who is the direct target of an
experimental (or control) manipulation of his/her
environment; or (3) with whom an investigator interacts
for the purpose of collecting data about that individual;
or (4) about whom an investigator obtains identifiable
private information for the purpose of collecting data
about that individual. Unless one or more of these
criteria is met, an individual is not a research partici-
pant.
The first criterion refers to individuals who are the intended
recipients of a study intervention. This includes health profession-
als targeted by an educational intervention designed to promote
evidence-based practice and patients targeted by a new therapy for
a disease.
The second criterion refers to individuals who are directly
targeted by an intervention delivered at the cluster level. This
includes patients in a CRT investigating alterations of health
delivery systems. It does not, however, include patients in a CRT
of an educational intervention delivered to health professionals
with the aim of promoting evidence-based practice. As argued in
more detail elsewhere [18], simply being a patient of a professional
participating in a CRT of an educational, knowledge translation,
or quality improvement intervention does not make one a research
participant. Although the professional may have received an
intervention aimed at improving practice, the professional is still
expected to act in the best interests of his or her patients and in
accordance with professional practice standards—the loyalty of
the health professional to the patient remains intact. Therefore,
the welfare interests of the patients of a health care provider
participating in a CRT are not jeopardized.
In some CRTs, clusters in the control arm are allocated to usual
practice or no treatment, i.e., individuals may be neither recipients
nor targets of any study interventions. However, when individuals
in the experimental arm of the study are considered research
participants, individuals in the control arm ought to be considered
research participants, as their interests may be affected by lack of
access to the study intervention or other appropriate care or
benefit, and thus, they are entitled to protection (see recommen-
dation 12).
The third and fourth criteria refer to individuals who provide
data by interacting with investigators (e.g., through focus groups,
interviews, or additional examinations) or individuals about whom
investigators obtain identifiable private information (e.g., through
review of patient health records). Individuals whose data are
provided to the research team in anonymized form (e.g., from
administrative data sources or registries) are not considered
research participants.
Many CRTs involve cluster members who do not meet the
criteria for research participants. For example, if the study
intervention is designed to promote evidence-based practice by
health professionals, and does not directly intervene in patient
care, and if the researchers do not interact with patients or collect
their identifiable private information, then those patients are not
research participants [18].
Obtaining Informed Consent
Recommendation 4: Researchers must obtain in-
formed consent from human research participants in a
CRT, unless a waiver of consent is granted by a REC
under specific circumstances.
The obligation to obtain informed consent stems from the
ethical principle of respect for persons, which requires that the
choices of autonomous individuals be respected [19]. To be valid,
such choices must be sufficiently informed, voluntary, and
considered. Therefore, unless a waiver of consent is granted by a
REC (see recommendation 6), researchers must seek the informed
consent of potential research participants (or their proxy decision
makers), and may enroll only those participants who provide
consent.
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In the informed consent process, researchers must provide
potential participants with adequate information about the
purpose of the study, study interventions and data collection
procedures, the potential benefits and risks of study participation,
and alternatives to participation. The aim is to enable participants
to make a reasonable determination about whether enrolling in
the study is consistent with their preferences and values. Detailed
disclosure requirements are enumerated in international and
national research ethics guidelines. Generally, informed consent
refers to randomization, study interventions, and data collection
procedures. However, in some CRTs different participants may
need to provide consent to different elements. For example, health
professionals as the recipients of an educational intervention may
need to consent to study interventions, whereas patients may need
to consent to data collection.
Recommendation 5: When participants’ informed
consent is required, but recruitment of participants is
not possible before randomization of clusters, research-
ers must seek participants’ consent for trial enrollment
as soon as possible after cluster randomization—that is,
as soon as the potential participant has been identified,
but before the participant has undergone any study
interventions or data collection procedures.
To be consistent with the moral purpose of informed consent,
researchers should strive to identify participants and seek their
consent before cluster allocation. In CRTs where identification
and recruitment is not possible before randomization of clusters,
participants may be legitimately enrolled following randomization
of clusters. Researchers should, however, seek a potential
participant’s consent for study interventions and data collection
procedures as soon as possible after the participant has been
identified, and before administering any study interventions or
data collection procedures. Seeking consent in this way after
randomization is consistent with the moral purpose of informed
consent, as potential participants may still freely choose whether or
not to enroll in the trial [19].
Although seeking consent after randomization is consistent with
the moral purpose of informed consent, researchers should be
aware that selection biases can arise in such cases and should
adopt design strategies that minimize the risk of bias [21,28–30].
Recommendation 6: A REC may approve a waiver or
alteration of consent requirements when (1) the re-
search is not feasible without a waiver or alteration of
consent, and (2) the study interventions and data
collection procedures pose no more than minimal risk.
If seeking consent for study interventions or data collection
procedures is not feasible (whether before or after randomization),
researchers should apply for a waiver or alteration of consent,
provided that study and data collection procedures pose no more
than minimal risk to research participants. In a waiver of consent,
the REC removes the requirement to obtain informed consent; in
an alteration of consent, the REC permits the alteration or
deletion of some of the standard elements of disclosure in the
informed consent. Minimal risk refers to the risks of daily life, and
includes the risks associated with routine physical examinations
and review of medical records. Additional examples of study
interventions and data collection procedures that pose only
minimal risk are enumerated in the research ethics literature
and ethics guidelines [31,32].
As stated previously, many CRTs pose only low risk to research
participants. The burden of demonstrating adequately to the REC
that (1) obtaining informed consent is infeasible and (2) study
participation poses only minimal risk falls to the researcher.
Feasibility will depend on a variety of factors including cluster size,
proximity of cluster members (and thus ease of contact),
complexity of the consent process, research infrastructure (such
as number of local health workers available to approach cluster
members), and research funding.
Some researchers may be concerned that information provided
to potential participants during the consent process will lead to
bias that would undermine the interpretability of study results
[33]. Rather than using a waiver of consent to address such
concerns, the researcher and REC should consider an alteration of
the consent process (such as blinding participants to their
allocation status). Alternatively, researchers may consider adopting
design features that address concerns about study validity while
still adequately protecting participants’ interests. For example, in
an incomplete block design, each arm receives an intervention and
simultaneously serves as a control for the other arm [34,35];
participants in both study arms are provided with similar
information during the consent process, thus equalizing any
nonspecific (Hawthorne) effects across the study arms. Researchers
should be aware that different consent procedures in the
intervention and control arms of the trial may lead to bias [29,30].
If obtaining informed consent is feasible for some but not all
study interventions or data collection procedures, then researchers
should obtain separate informed consent, where possible, for each
procedure. For instance, in a CRT involving a cluster-level public
health intervention for which a waiver of consent for the study
intervention has been obtained, informed consent for data
collection procedures may nonetheless be required.
In cases in which a waiver of consent has been granted,
researchers and RECs may nonetheless consider making informa-
tion about the study available to the eligible study population. This
might occur, for example, via distribution of leaflets, poster
placement in locations such as schools or physicians’ offices, or
public health bulletins. However, distribution of information about
the study should not be construed as satisfying the requirement for
informed consent. Rather, it is an additional step that researchers
and RECs may pursue to demonstrate respect for persons when
informed consent is not possible.
Recommendation 7: Researchers must obtain in-
formed consent from professionals or other service
providers who are research participants unless condi-
tions for a waiver or alteration of consent are met.
Many CRTs deliver an intervention to professionals or other
service providers (e.g., physicians, midwives, teachers) in order to
produce an effect on cluster members (e.g., patients, students).
These professionals or service providers are research participants
and entitled to ethical protections. This includes the requirement
for researchers to obtain their informed consent, unless a waiver of
consent is granted by a REC (see recommendation 6).
It has been argued that health professionals have an obligation
to participate in research that may improve patient care [36]. This
prima facie moral obligation may indeed provide health profes-
sionals with a reason to agree to study participation when
approached for informed consent. It does not, however, obviate
the need to obtain their informed consent in specific CRTs when
they are research participants. Consent discussions with these
participants should include career-related risks, including risks due
to detection of negligence or incompetence. Data about profes-
sional or provider performance should be kept confidential within
the research team, unless circumstances arise that mandate
disclosure to a professional certifying or licensing body.
Conditions for a waiver or alteration of consent may be met in a
variety of circumstances involving professionals in CRTs (see
recommendation 6). Provided the requirement of minimal risk is
met, these circumstances include the following: when the number
PLOS Medicine | www.plosmedicine.org 5 November 2012 | Volume 9 | Issue 11 | e1001346
of professionals allocated to study interventions makes obtaining
their informed consent infeasible in terms of either logistics or
resources required; when cluster-level interventions mean that the
professional cannot meaningfully refuse the study intervention (as
when study interventions are delivered to entire health care teams
as a unit); and when the researchers have grounds to believe that
incomplete uptake of the study intervention or information
provided to potential research participants during the informed
consent process would threaten the validity of the trial results.
Gatekeepers
Gatekeepers are individuals or bodies who may be called upon
to protect the group-based interests that are affected by enrollment
in a CRT [20]. Due to the challenges in obtaining individual
informed consent in CRTs, researchers have historically turned to
gatekeepers to perform a variety of roles, including providing
proxy consent on behalf of individual cluster members, and giving
permission to enroll clusters in trials.
Recommendation 8: Gatekeepers should not provide
proxy consent on behalf of individuals in their cluster.
Legitimate proxy consent requires that the proxy decision
maker be well acquainted with the potential research participant’s
values and beliefs, making the proxy decision maker well situated
to make decisions consistent with the potential participant’s wishes
or interests. Further, proxy decision making is typically employed
when the potential participant is incapable of making the decision
for him- or herself. In CRTs, neither of these conditions is met,
and so gatekeepers are not in a position to provide legitimate
proxy consent on behalf of individual cluster members [20].
Recommendation 9: When a CRT may substantially
affect cluster or organizational interests, and a gate-
keeper possesses the legitimate authority to make
decisions on the cluster or organization’s behalf, the
researcher should obtain the gatekeeper’s permission to
enroll the cluster or organization in the trial. Such
permission does not replace the need for the informed
consent of research participants, when it is required.
Gatekeepers may play an important role in the protection of
cluster interests. When a CRT may have a substantial effect on a
cluster or organization, obtaining the permission of a gatekeeper is
one means of protecting the interests of the cluster or organization.
For example, in a school-based trial, the school principal acting as
a gatekeeper may provide permission to enroll a school in the
CRT, after considering the impact on the school including
availability of staff, financial implications of participation, and the
likelihood that teachers or students would be willing to participate.
Gatekeepers may provide or withhold permission to enroll a
cluster only when they have legitimate authority to do so. The
legitimacy of gatekeepers’ authority depends on the extent to
which the following conditions are met: (1) their role within the
cluster or organization endows them with the authority to make
decisions on behalf of the cluster, e.g., they hold a political office or
an administrative position within an organization that clearly gives
them the relevant decision making authority, and (2) cluster
members recognize the gatekeeper’s authority. In situations where
cluster members do not clearly accept the gatekeeper’s authority to
make the particular decision about enrollment, the legitimacy of
that authority is questionable. Although a gatekeeper may
legitimately give permission for cluster participation, gatekeeper
permission is not a substitute for the informed consent of
individual research participants in a CRT.
Some CRTs can have multiple levels of gatekeepers, e.g., one
gatekeeper with authority over several clusters, but each cluster
also having its own gatekeeper. Researchers and RECs should
strive to identify situations in which the interests of different
stakeholders within a CRT may conflict. For instance, the interests
of an organization (such as a health care organization or school
board) may conflict with the interests of clusters within that
organization (such as physician practices or schools) or with the
interests of individual cluster members (such as patients or
students). Whereas requiring permission from a gatekeeper (such
as an administrative head, board of governors, or school board)
may serve to protect some stakeholders’ interests, that gatekeeper
may not be in a position to consider the interests of all
stakeholders. Researchers and RECs should consider and, where
possible, seek to safeguard the interests of all individuals or groups
who may be affected by study interventions in a CRT.
The decision by a gatekeeper to withdraw a cluster from an
ongoing CRT may have serious consequences for the participants
as well as for the scientific validity of the study. Accordingly,
researchers should do what they can to ensure that gatekeepers are
unlikely to have reason to withdraw their cluster. Where possible,
CRTs should be designed to minimize the effect of cluster
withdrawal on study validity.
Recommendation 10: When CRT interventions may
substantially affect cluster interests, researchers should
seek to protect cluster interests through cluster consul-
tation to inform study design, conduct, and reporting.
Where relevant, gatekeepers can often facilitate such a
consultation.
Gatekeepers may facilitate consultation between researchers
and cluster members about the goals, design, and implementation
of the study, as well as consultation about the research findings
before they are disseminated [20]. Mechanisms for cluster
consultation may include open public fora, community advisory
boards, meetings with opinion leaders, presentations at religious or
civic organizations, and the use of radio, television, or the Internet.
These activities may help to protect and promote group interests
by subjecting the study to examination and discussion by those
whose interests may be affected or by some set of individuals who
are familiar with those whose interests may be affected. Whether
and to what extent cluster consultation needs to be undertaken will
depend on the particular circumstances of the study. Recommen-
dations from cluster consultation are not binding, and, where there
are good reasons to do so, researchers may decline to make
suggested changes to a study.
Assessing Benefits and Harms
Establishing what constitutes a reasonable balance of harms and
benefits is a central issue in research ethics. Component analysis
provides researchers and RECs with a systematic approach to the
ethical analysis of study benefits and harms (see Text S3 for
general ethical principles) [37].
In CRTs evaluating different models of health service delivery,
public health promotion campaigns, and educational interven-
tions, ‘‘therapeutic procedures’’ often do not offer the participant
the prospect of therapeutic benefit as it is traditionally understood
in the medical sense. Instead, they offer different types of benefits,
such as educational benefit. Identifying therapeutic procedures in
CRTs therefore requires a broader definition in which therapeutic
procedure refers to any intervention that is part of the
experimental intervention, including particular components of a
multifaceted, complex intervention. Further, the analysis of the
benefits and harms of CRTs must take into account the fact that
CRTs often involve effects on groups, health systems, and society
as a whole.
Central to clinical equipoise is uncertainty about the compar-
ative benefits and harms of the intervention in the experimental
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arm versus the control arm, according to a community of experts
[17]. In individual patient randomized trials of clinical interven-
tions, the relevant evidence relates to the balance of likely benefits
and harms that might be incurred by individual research
participants. CRTs may address questions that focus on the
effectiveness of interventions solely for individual patients, in
which case standard clinical equipoise considerations apply;
however, they may also address public health questions, health
systems questions, and knowledge translation or quality improve-
ment questions. These latter types of questions are of interest to a
variety of stakeholders; this suggests that the relevant evidence in
CRTs may be broader, and justification for CRTs may need to
take potential effects on a range of stakeholders into account.
Component analysis usefully directs the attention of researchers
and RECs to the justification of the study intervention, control
conditions, and data collection procedures when considering the
benefits and harms of a CRT.
Recommendation 11: The researcher must ensure
that the study intervention is adequately justified. The
benefits and harms of the study intervention must be
consistent with competent practice in the field of study
relevant to the CRT.
The ethical concept of clinical equipoise requires uncertainty
about the comparative benefits of the intervention in the
experimental arm versus the control arm, according to a
community of experts. This means that the benefits and harms
of the study intervention must be consistent with competent
practice in the field of study relevant to the CRT. In a CRT, study
interventions may offer benefits to individual participants (in
which case standard clinical equipoise considerations apply), or
they may potentially benefit the clusters, organizations, or
communities to which the research participants belong. The risks
of study interventions may be borne by a stakeholder who may not
necessarily derive benefit. So, it is difficult to compare directly the
risks and potential benefits of study interventions. Rather, the
REC should ensure that study interventions are consistent with
competent practice in the particular field of study relevant to the
CRT, such as medical practice, public health, health policy, or
education. This requires the REC to appeal to evidence and the
opinion of expert practitioners in the relevant field.
Random assignment of study interventions is justified if there is
uncertainty in the relevant community of experts as to the
preferred practice. The community of expert practitioners varies
depending on the type of research question. For instance, public
health clinicians are the relevant community of expert practition-
ers for public health questions, and policy makers or analysts are
the relevant expert community for health policy questions. The
scope of evidence relevant to the benefit–harm analysis may be
broad, for example, when outcomes such as equity or costs are key
issues for the research question. In the preparation of the study
protocol, researchers should undertake a detailed review of the
evidence on benefits and harms of the study intervention. Further,
researchers may provide evidence regarding uncertainty among
the relevant community of expert practitioners about the
comparative benefits of the intervention in the experimental arm
versus the control arm.
Recommendation 12: Researchers must adequately
justify the choice of the control condition. When the
control arm is usual practice or no treatment, individ-
uals in the control arm must not be deprived of effective
care or programs to which they would have access, were
there no trial.
When the control arm is usual practice or no treatment,
individuals in the control arm must not be deprived of effective
care or programs to which they would have access if there were no
study being conducted. Delayed provision of the study interven-
tion to the individuals in the control arm does not justify depriving
them of access to effective care or programs to which they would
otherwise have access. As a minimum, clinical equipoise requires
that the control arm should be given usual care within the study
context.
Researchers and RECs may consider whether the control arm
should receive some form of augmented care. In the context of a
pragmatic CRT [38] of health policy or knowledge translation that
aims to inform local policy, however, augmented care in the
control arm may interfere with the scientific validity of the study
by increasing the chances of a false negative result, or reducing the
study’s generalizability [33]. Thus, researchers and RECs need to
give careful consideration to the advantages and disadvantages of
this approach.
When reviewing the study protocol, the REC should consider
whether and when the control clusters will receive the study
intervention if the study intervention is shown to be effective.
Recommendation 13: Researchers must ensure that
data collection procedures are adequately justified. The
risks associated with data collection procedures must
(1) be minimized consistent with sound design and (2)
stand in reasonable relation to the knowledge to be
gained.
Data collection procedures, including interviews, surveys,
additional physical examinations that are not part of standard
care, review of medical records, and the collection of economic
information, are unlikely to benefit individuals or clusters directly.
Rather, data collection procedures may benefit society in terms of
new knowledge gained from the study. Researchers must,
therefore, minimize the risks associated with data collection
procedures consistent with sound design, and ensure that these
risks stand in reasonable relation to the knowledge to be gained.
Use of electronic medical record or administrative data sources
is to be recommended, as the burden and risk of data collection is
much reduced, provided that (1) the raw data are fully de-
identified prior to reaching the researcher and (2) reliable
procedures for preventing re-identification are maintained
throughout the research process.
Protecting Vulnerable Participants
Vulnerable research participants fall into one or more of four
broad categories: (1) children, (2) incapable adults (i.e., adults
unable to provide informed consent), (3) people at undue risk of
harm as a result of study participation, and (4) people in
subordinate positions within social or organizational structures.
CRTs may legitimately include vulnerable participants, provided
that adequate protections for them are in place. Standard
protections for vulnerable participants are discussed in Text S3
and are outlined in various national and international ethics
guidelines.
Including vulnerable participants in CRTs poses the special
challenge that their presence within clusters may be hidden, and
thus, investigators may fail to employ the required standard
protections. The presence of vulnerable participants may go
unnoticed for two reasons: first, clusters may contain within them a
small proportion of vulnerable individuals within apparently less
vulnerable groups; and second, there may be individuals in a
cluster who are not normally thought of as vulnerable, but who are
vulnerable by virtue of their cluster membership. Examples of such
individuals are health service staff, teachers, or other employees
who may feel pressured to participate in a CRT involving their
institution.
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Recommendation 14: Clusters may contain vulnerable
participants. In these circumstances, researchers and
RECs must consider whether additional protections are
needed.
Researchers and RECs should be mindful of the possibility that
clusters may contain a mix of vulnerable and non-vulnerable
participants. Where applicable, RECs should ensure that proposed
consent procedures are appropriate for vulnerable participants
within the cluster, and that study benefits and harms to such
individuals are acceptable. For instance, a CRT studying
programs for community treatment of mental illness may affect
people living in group homes for the mentally ill. For this
vulnerable subgroup, the REC will wish to ensure that consent
procedures, including capacity assessment and the appropriate use
of substitute decision makers, are appropriate. The REC may
consult with an independent advocate or committee representing
group home clients to ensure that people living in group homes are
not unduly burdened by changes in access to community services.
In some cases, the study intervention may run the risk of
exacerbating preexisting inequalities within clusters [39]. Where
applicable, the REC should take this potential adverse outcome
into account in the assessment of study benefits and harms.
The presence of vulnerable participants within a cluster does
not preclude the use of a waiver of consent for all human research
participants in the cluster.
Recommendation 15: When individual informed con-
sent is required and there are individuals who may be
less able to choose participation freely because of their
position in a cluster or organizational hierarchy, RECs
should pay special attention to recruitment, privacy,
and consent procedures for those participants.
Some CRTs are conducted in the setting of clusters or
organizations in which some members may be less able to express
a free choice about trial participation because of their position
within the hierarchy. When investigators are recruiting or
obtaining consent from these individuals, they should conduct
informed consent negotiations in such a way as to limit the
potential for coercive influence from cluster or organizational
leaders. For instance, consent negotiations should be conducted
without the presence of cluster or organizational leaders, and
cluster or organizational leaders should not be informed of the
identities of those who agree to or decline study participation.
Vulnerability of this type does not preclude the appropriate use
of a waiver of consent.
Discussion
This consensus statement aims to provide researchers and RECs
with guidance on the ethical design and conduct of CRTs in
health research. General ethical principles are broadly understood
to govern the practice of health research, but their application is
complicated by design features of CRTs. As part of a five-year
research project preceding the consensus process, the research
team documented the reporting of ethical issues in CRTs and
sought the perspectives of trialists and REC chairs on the ethical
challenges they faced in the design, review, and conduct of CRTs.
Background papers supplied detailed ethical analyses of the issues
identified in this work, including the identification of research
participants, informed consent, the role of gatekeepers, the balance
of benefits and harms, and the protection of vulnerable
participants. This combination of empirical work and ethical
analysis provided the consensus process with a rich foundation,
and helped ensure that the resulting consensus statement is
reasonably comprehensive. Given the rapidly expanding nature of
the field, however, we expect that significant revisions and
additions to this document will be needed over the next five years.
The consensus statement is the result of a transparent and
robust consensus process. The research team strived for transpar-
ency by publishing the project protocol and background papers in
Trials (an open-access journal), posting project materials on a
publically accessible wiki, providing a free webcast of the open
portion of the consensus meeting, and holding an open
consultation on the draft consensus statement with point-by-point
response to all comments raised. The formal consensus process
was led by a chair who is experienced in guideline development.
Careful attention was paid to the small group processes of the
expert panel to minimize the risk of psychosocial biases. Expert
panel members were encouraged to question, comment on, and
debate issues throughout the consensus process. Two drafts of the
consensus statement were circulated to expert panel members after
the closed meeting, which allowed members to raise any
outstanding concerns they felt they had not been adequately
addressed previously. Anecdotally, many expert panel members
commented favorably on the quality of the consensus process.
The consensus statement is subject to limitations common to
consensus processes. The research team identified participants
from a variety of sources to represent the range of constituencies
and perspectives that it felt should be represented. However, not
all invitees agreed to participate, and some perspectives were
underrepresented. For example, the expert panel was to include a
trialist and a REC chair from a low- or middle-income country
(LMIC), but a REC chair who could participate was not identified.
As a result, LMIC perspectives were underrepresented. The
authors believe that the consensus statement’s applicability to
CRTs in LMIC settings is supported by a number of factors,
including consideration of LMIC examples in the background
papers, the inclusion in the expert panel of six trialists with
extensive experience in LMIC settings and members with
expertise in the ethics of research in LMICs, and extensive
discussion of LMIC issues in the closed meeting. As greater
representation from LMICs could nonetheless have brought issues
to the fore that were not considered, we recommend that
subsequent revisions include greater LMIC representation.
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